ArticleJournal of neuro-oncology2026
Reirradiation outcomes following salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) to recurrent primary non-glial brain tumors.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and safety of salvage conventionally fractionated Gamma Knife stereotactic radiotherapy (SFGK) reirradiation for recurrent, previously irradiated primary non-glial brain tumours.
methodsConsecutive patients underwent SFGK from 2019 to 2024 for progressive, previously definitively irradiated primary intracranial tumours. The primary endpoint was local progression-free survival (LPFS). Secondary endpoints were overall survival (OS) and safety.
resultsTwenty-six patients (44 tumours) were treated. There were 34 meningiomas (77%), of which 28 were WHO Grade 2. The median time from prior radiotherapy was 50.4 months (IQR 19.7-86.8). The SFGK prescription dose was 50.4 Gy in 28 fractions in 37 tumors (84%). The median cumulative prescription EQD2 was 102.7 Gy (IQR 99.6-114.6) for those with one prior radiotherapy course. The median normal brain EQD2 was 99.2 Gy (97.9-117.5) for those with one prior radiotherapy course. The median follow-up was 18.1 months (IQR 10.5-28.2). Overall LPFS at 12 and 24 months was 91.0% (95% CI 73.6-97.2%) and 75.1% (95% CI 51.0-88.6%), respectively. OS at 12 and 24 months was 96.2% (95% CI 75.7-99.4%) and 83.2% (95% CI 54.8-94.6%), respectively. For the meningioma cohort, 12- and 24-month LPFS was 90.6% (95% CI 65.7-97.7%) and 74.1% (95% CI 42.7-90.0%), respectively. Grade 3 radionecrosis occurred in two patients (6.9%), one case of Grade 3 progressive intracranial hemorrhage (3.4%), and no Grade 4 or 5 events were observed.
conclusionsSFGK re-irradiation is feasible and well tolerated, achieving durable local control in recurrent non-glial brain tumours with few serious adverse events despite high cumulative doses.
Indexed as
Identifiers
42758433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.